278 related articles for article (PubMed ID: 32301565)
1. Comparison of various treatment options for canine atopic dermatitis: a blinded, randomized, controlled study in a colony of research atopic beagle dogs.
Marsella R; Ahrens K; Wilkes R; Trujillo A; Dorr M
Vet Dermatol; 2020 Aug; 31(4):284-e69. PubMed ID: 32301565
[TBL] [Abstract][Full Text] [Related]
2. A randomised, double-blinded, controlled trial to determine the efficacy of combined therapy of oclacitinib and marine oil extract PCSO-524 in dogs with atopic dermatitis.
Nishiyama T; Kusakabe M; Imanishi I; Hisano T; Fukamachi T; Taguchi N; Iyori K; Hsiao YH
Vet Dermatol; 2023 Dec; 34(6):523-531. PubMed ID: 37485602
[TBL] [Abstract][Full Text] [Related]
3. The influence of treatment with lokivetmab on transepidermal water loss (TEWL) in dogs with spontaneously occurring atopic dermatitis.
Szczepanik M; Wilkołek P; Gołyński M; Sitkowski W; Taszkun I; Toczek W
Vet Dermatol; 2019 Aug; 30(4):330-e93. PubMed ID: 31090122
[TBL] [Abstract][Full Text] [Related]
4. A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs.
Little PR; King VL; Davis KR; Cosgrove SB; Stegemann MR
Vet Dermatol; 2015 Feb; 26(1):23-30, e7-8. PubMed ID: 25496303
[TBL] [Abstract][Full Text] [Related]
5. A pilot study on the effect of oclacitinib on epicutaneous sensitization and transepidermal water loss in a colony of atopic beagle dogs.
Marsella R; Ahrens K
Vet Dermatol; 2018 Oct; 29(5):439-e146. PubMed ID: 29926994
[TBL] [Abstract][Full Text] [Related]
6. A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis.
Michels GM; Ramsey DS; Walsh KF; Martinon OM; Mahabir SP; Hoevers JD; Walters RR; Dunham SA
Vet Dermatol; 2016 Dec; 27(6):478-e129. PubMed ID: 27647569
[TBL] [Abstract][Full Text] [Related]
7. A blinded, randomized clinical trial evaluating the efficacy and safety of lokivetmab compared to ciclosporin in client-owned dogs with atopic dermatitis.
Moyaert H; Van Brussel L; Borowski S; Escalada M; Mahabir SP; Walters RR; Stegemann MR
Vet Dermatol; 2017 Dec; 28(6):593-e145. PubMed ID: 28906040
[TBL] [Abstract][Full Text] [Related]
8. Correlation between clinical efficacy on pruritus and serum interleukin-31 levels in dogs with atopic dermatitis treated with lokivetmab.
Calesso JR; Marques VS; de Carvalho OV; Costa-Val AP
Pol J Vet Sci; 2023 Jun; 26(2):231-238. PubMed ID: 37389418
[TBL] [Abstract][Full Text] [Related]
9. Preliminary evaluation of two bathing methods for the management of Malassezia overgrowth in dogs with atopic dermatitis.
Esumi M; Kanda S; Shimoura H; Hsiao YH; Iyori K
Vet Dermatol; 2021 Jun; 32(3):228-e59. PubMed ID: 33844368
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of 0.0584% hydrocortisone aceponate topical spray and systemic oclacitinib combination therapy in dogs with atopic dermatitis: a randomized, double-blinded, placebo-controlled trial.
Takahashi J; Kanda S; Imanishi I; Hisano T; Fukamachi T; Taguchi N; Momiyama S; Nishiyama S; Motegi T; Iyori K
Vet Dermatol; 2021 Apr; 32(2):119-e25. PubMed ID: 33185330
[TBL] [Abstract][Full Text] [Related]
11. A retrospective analysis of the use of lokivetmab in the management of allergic pruritus in a referral population of 135 dogs in the western USA.
Souza CP; Rosychuk RAW; Contreras ET; Schissler JR; Simpson AC
Vet Dermatol; 2018 Dec; 29(6):489-e164. PubMed ID: 30141223
[TBL] [Abstract][Full Text] [Related]
12. A randomised controlled trial testing the rebound-preventing benefit of four days of prednisolone during the induction of oclacitinib therapy in dogs with atopic dermatitis.
Olivry T; Lokianskiene V; Blanco A; Mestre PD; Bergvall K; Beco L
Vet Dermatol; 2023 Apr; 34(2):99-106. PubMed ID: 36330780
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of a 0.0584% hydrocortisone aceponate spray in the management of canine atopic dermatitis: a randomised, double blind, placebo-controlled trial.
Nuttall T; Mueller R; Bensignor E; Verde M; Noli C; Schmidt V; Rème C
Vet Dermatol; 2009 Jun; 20(3):191-8. PubMed ID: 19374721
[TBL] [Abstract][Full Text] [Related]
14. A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis.
Cosgrove SB; Wren JA; Cleaver DM; Walsh KF; Follis SI; King VI; Tena JK; Stegemann MR
Vet Dermatol; 2013 Dec; 24(6):587-97, e141-2. PubMed ID: 24581322
[TBL] [Abstract][Full Text] [Related]
15. Hair cortisol concentration, disease severity and quality of life in dogs with atopic dermatitis during lokivetmab therapy.
Stuart Marques V; Calesso JR; de Carvalho OV; da Costa-Val Bicalho AP
Vet Dermatol; 2023 Aug; 34(4):339-347. PubMed ID: 37165693
[TBL] [Abstract][Full Text] [Related]
16. Comparable efficacy of a topical 0.0584% hydrocortisone aceponate spray and oral ciclosporin in treating canine atopic dermatitis.
Nuttall TJ; McEwan NA; Bensignor E; Cornegliani L; Löwenstein C; Rème CA
Vet Dermatol; 2012 Feb; 23(1):4-10, e1-2. PubMed ID: 21718368
[TBL] [Abstract][Full Text] [Related]
17. The effect of a mixed cannabidiol and cannabidiolic acid based oil on client-owned dogs with atopic dermatitis.
Loewinger M; Wakshlag JJ; Bowden D; Peters-Kennedy J; Rosenberg A
Vet Dermatol; 2022 Aug; 33(4):329-e77. PubMed ID: 35644533
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of short-term combination of intralymphatic allergen immunotherapy and lokivetmab treatment in canine atopic dermatitis: A double-blinded, controlled, randomised study.
van Amersfort K; Vernooij JCM; van der Lee A
Vet Dermatol; 2023 Oct; 34(5):373-384. PubMed ID: 37186491
[TBL] [Abstract][Full Text] [Related]
19. A masked, randomised clinical trial evaluating the efficacy and safety of lokivetmab compared to saline control in client-owned dogs with allergic dermatitis.
Van Brussel L; Moyaert H; Escalada M; Mahabir SP; Stegemann MR
Vet Dermatol; 2021 Oct; 32(5):477-e131. PubMed ID: 34180084
[TBL] [Abstract][Full Text] [Related]
20. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life.
Cosgrove SB; Cleaver DM; King VL; Gilmer AR; Daniels AE; Wren JA; Stegemann MR
Vet Dermatol; 2015 Jun; 26(3):171-9, e35. PubMed ID: 25688708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
